BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

11373

532523

BIOCON

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

BIOCON LIMITED. performance

Today’s low

Today’s high

₹ 317.00 ₹ 325.20
₹ 321.80

52 week low

52 week high

₹ 269.55 ₹ 404.70
₹ 321.80

Open Price

₹ 319.45

Prev. Close

₹ 318.85

Volume (Shares)

2632538.00

Total traded value

₹ 8471.50

Upper Circuit

₹ 350.70

Lower Circuit

₹ 287.00

info

BIOCON LIMITED. Share Price Update

As of the latest trading session, BIOCON LIMITED. share price is currently at ₹ 321.8, which is up by ₹ 2.94 from its previous closing. Today, the stock has fluctuated between ₹ 317.00 and ₹ 325.20. Over the past year, BIOCON LIMITED. has achieved a return of 7.78 %. In the last month alone, the return has been -5.10 %. Read More...

BIOCON LIMITED. fundamentals


  • Market cap (Cr)

    38,635.31

  • P/E Ratio (TTM)

    64.21

  • Beta

    1.27

  • Book Value / share

    90.69

  • Return on equity

    0.97%

  • EPS (TTM)

    0.12

  • Dividend yield

    0.16%

  • Net profit/quarter (Cr)

    584.00

info icon alternate text
  • Market cap (Cr)

    38,623.30

  • P/E Ratio (TTM)

    64.21

  • Beta

    1.22

  • Book Value / share

    90.69

  • Return on equity

    0.97%

  • EPS (TTM)

    0.12

  • Dividend yield

    0.16%

  • Net profit/quarter (Cr)

    584.00

info icon alternate text

BIOCON LIMITED. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 562.80
Operating Expense 630.59
Net Profit 584.00
Net Profit Margin (%) 103.76
Earnings Per Share (EPS) 4.88
EBITDA 702.99
Effective Tax Rate (%) 3.29
Particulars SEP 2024 (Values in Cr)
Revenue 525.40
Operating Expense 578.00
Net Profit 3.20
Net Profit Margin (%) 0.60
Earnings Per Share (EPS) 0.03
EBITDA 111.10
Effective Tax Rate (%) 84.68
Particulars JUN 2024 (Values in Cr)
Revenue 510.60
Operating Expense 551.40
Net Profit 0.90
Net Profit Margin (%) 0.17
Earnings Per Share (EPS) 0.01
EBITDA 86.80
Effective Tax Rate (%) 18.18
Particulars MAR 2024 (Values in Cr)
Revenue 532.60
Operating Expense 549.70
Net Profit 14.00
Net Profit Margin (%) 2.62
Earnings Per Share (EPS) 0.12
EBITDA 91.10
Effective Tax Rate (%) 35.77
Particulars DEC 2023 (Values in Cr)
Revenue 562.80
Operating Expense 578.40
Net Profit 24.00
Net Profit Margin (%) 4.26
Earnings Per Share (EPS) 0.20
EBITDA 119.80
Effective Tax Rate (%) 27.05
Particulars MAR 2024 (Values in Cr)
Revenue 2127.30
Operating Expense 2184.50
Net Profit 119.30
Net Profit Margin (%) 5.60
Earnings Per Share (EPS) 1.00
EBITDA 470.20
Effective Tax Rate (%) 20.62
Particulars MAR 2023 (Values in Cr)
Revenue 1992.90
Operating Expense 2155.90
Net Profit 2848.40
Net Profit Margin (%) 142.92
Earnings Per Share (EPS) 23.87
EBITDA 3157.70
Effective Tax Rate (%) 4.13
Particulars MAR 2022 (Values in Cr)
Revenue 1738.20
Operating Expense 1785.70
Net Profit 86.10
Net Profit Margin (%) 4.95
Earnings Per Share (EPS) 0.72
EBITDA 248.30
Effective Tax Rate (%) 38.36
Particulars MAR 2021 (Values in Cr)
Revenue 2028.40
Operating Expense 1819.80
Net Profit 280.50
Net Profit Margin (%) 13.82
Earnings Per Share (EPS) 2.36
EBITDA 462.70
Effective Tax Rate (%) 21.82
Particulars MAR 2020 (Values in Cr)
Revenue 1988.40
Operating Expense 1801.60
Net Profit 440.90
Net Profit Margin (%) 22.17
Earnings Per Share (EPS) 3.72
EBITDA 647.40
Effective Tax Rate (%) 20.41
Particulars MAR 2024 (Values in Cr)
Book Value / Share 164.77
ROE % 6.89
ROCE % 6.35
Total Debt to Total Equity 0.91
EBITDA Margin 27.57
Particulars MAR 2023 (Values in Cr)
Book Value / Share 148.81
ROE % 6.64
ROCE % 5.68
Total Debt to Total Equity 0.88
EBITDA Margin 24.57
Particulars MAR 2022 (Values in Cr)
Book Value / Share 70.23
ROE % 10.84
ROCE % 7.55
Total Debt to Total Equity 0.60
EBITDA Margin 24.35
Particulars MAR 2021 (Values in Cr)
Book Value / Share 63.55
ROE % 11.81
ROCE % 8.68
Total Debt to Total Equity 0.50
EBITDA Margin 25.77
Particulars MAR 2020 (Values in Cr)
Book Value / Share 55.87
ROE % 13.61
ROCE % 12.17
Total Debt to Total Equity 0.40
EBITDA Margin 28.62
Particulars MAR 2024 (Values in Cr)
Book Value / Share 90.88
ROE % 0.97
ROCE % 2.61
Total Debt to Total Equity 0.15
EBITDA Margin 21.31
Particulars MAR 2023 (Values in Cr)
Book Value / Share 90.91
ROE % -0.14
ROCE % 1.50
Total Debt to Total Equity 0.07
EBITDA Margin 13.60
Particulars MAR 2022 (Values in Cr)
Book Value / Share 67.40
ROE % 1.08
ROCE % 1.72
Total Debt to Total Equity 0.01
EBITDA Margin 14.28
Particulars MAR 2021 (Values in Cr)
Book Value / Share 65.88
ROE % 3.63
ROCE % 4.60
Total Debt to Total Equity 0.00
EBITDA Margin 22.81
Particulars MAR 2020 (Values in Cr)
Book Value / Share 62.80
ROE % 4.16
ROCE % 5.17
Total Debt to Total Equity 0.01
EBITDA Margin 24.32
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 2258.70
Total Assets 56070.70
Total Liabilities 56070.70
Total Equity 25274.80
Share Outstanding 1200600000
Price to Book Ratio 2.91
Return on Assets (%) 1.82
Return on Capital (%) 2.49
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 2400.10
Total Assets 52042.80
Total Liabilities 52042.80
Total Equity 22488.80
Share Outstanding 1200600000
Price to Book Ratio 2.27
Return on Assets (%) 0.88
Return on Capital (%) 1.15
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1747.50
Total Assets 20394.00
Total Liabilities 20394.00
Total Equity 9470.00
Share Outstanding 1200600000
Price to Book Ratio 4.96
Return on Assets (%) 3.17
Return on Capital (%) 4.51
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2015.40
Total Assets 18522.30
Total Liabilities 18522.30
Total Equity 8507.60
Share Outstanding 1200000000
Price to Book Ratio 6.21
Return on Assets (%) 3.99
Return on Capital (%) 5.76
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 998.60
Total Assets 14443.80
Total Liabilities 14443.80
Total Equity 7383.10
Share Outstanding 1200000000
Price to Book Ratio 4.31
Return on Assets (%) 5.18
Return on Capital (%) 8.07
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 585.70
Total Assets 13768.20
Total Liabilities 13768.20
Total Equity 10912.30
Share Outstanding 1200600000
Price to Book Ratio 2.91
Return on Assets (%) 0.86
Return on Capital (%) 0.92
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 720.30
Total Assets 13029.90
Total Liabilities 13029.90
Total Equity 10916.00
Share Outstanding 1200600000
Price to Book Ratio 2.27
Return on Assets (%) 21.86
Return on Capital (%) 23.32
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 689.30
Total Assets 8869.00
Total Liabilities 8869.00
Total Equity 8092.90
Share Outstanding 1200600000
Price to Book Ratio 4.96
Return on Assets (%) 0.97
Return on Capital (%) 1.05
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 601.20
Total Assets 8573.70
Total Liabilities 8573.70
Total Equity 7907.10
Share Outstanding 1200000000
Price to Book Ratio 6.21
Return on Assets (%) 3.27
Return on Capital (%) 3.55
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 375.30
Total Assets 8310.80
Total Liabilities 8310.80
Total Equity 7537.30
Share Outstanding 1200000000
Price to Book Ratio 4.31
Return on Assets (%) 5.30
Return on Capital (%) 5.85
Particulars MAR 2024 (Values in Cr)
Net Income 1297.80
Cash from Operations 3246.20
Cash from Investing -1004.50
Cash from Financing -2332.70
Net change in Cash -383.30
Free Cash Flow 4926.70
Particulars MAR 2023 (Values in Cr)
Net Income 643.00
Cash from Operations 2081.10
Cash from Investing -14281.80
Cash from Financing 13048.70
Net change in Cash 619.40
Free Cash Flow 3677.10
Particulars MAR 2022 (Values in Cr)
Net Income 771.60
Cash from Operations 1438.60
Cash from Investing -1699.10
Cash from Financing 242.10
Net change in Cash -280.40
Free Cash Flow 3136.39
Particulars MAR 2021 (Values in Cr)
Net Income 846.20
Cash from Operations 1353.50
Cash from Investing -3624.70
Cash from Financing 2564.00
Net change in Cash 99.00
Free Cash Flow 2870.40
Particulars MAR 2020 (Values in Cr)
Net Income 870.90
Cash from Operations 1627.20
Cash from Investing -1558.90
Cash from Financing 387.60
Net change in Cash 111.80
Free Cash Flow 3231.40
Particulars MAR 2024 (Values in Cr)
Net Income 119.30
Cash from Operations -95.70
Cash from Investing -296.40
Cash from Financing 343.60
Net change in Cash -76.00
Free Cash Flow 206.00
Particulars MAR 2023 (Values in Cr)
Net Income 2848.40
Cash from Operations 260.40
Cash from Investing -1177.80
Cash from Financing 1039.40
Net change in Cash 80.90
Free Cash Flow 522.30
Particulars MAR 2022 (Values in Cr)
Net Income 86.10
Cash from Operations 76.00
Cash from Investing -305.60
Cash from Financing 112.00
Net change in Cash -146.00
Free Cash Flow 315.20
Particulars MAR 2021 (Values in Cr)
Net Income 280.50
Cash from Operations 632.60
Cash from Investing -711.20
Cash from Financing 27.80
Net change in Cash -112.10
Free Cash Flow 780.30
Particulars MAR 2020 (Values in Cr)
Net Income 440.90
Cash from Operations 477.80
Cash from Investing -212.90
Cash from Financing -128.90
Net change in Cash 45.30
Free Cash Flow 673.10
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

BIOCON LIMITED. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
321.80 0.92 redarrow
red-green-graph indicator
15 Bearish
1 Bullish
  • 5 Days 321.70
  • 26 Days 328.50
  • 10 Days 323.80
  • 50 Days 334.50
  • 12 Days 324.50
  • 100 Days 340.90
  • 20 Days 326.90
  • 200 Days 338.10
318.77 PIVOT

First Support

315.08

First Resistance

324.53

Second Support

309.32

Second Resistance

328.22

Third Support

305.63

Third Resistance

333.98

RSI

43.96

ADX

10.96

MACD

-4.02

Williams % R

-50.99

Commodity Channel Index (CCI)

-61.91

Date

2025-04-30

Week

1073980.00

Same Day

1177965.00

Month

868347.00

1 Year

1.27

3 Year

1.05

Over 1 Month

-5.10%

down

Over 1 Year

7.78%

down

Over 3 Months

-9.85%

down

Over 3 Years

-4.78%

down

Over 6 Months

0.34%

down

Over 5 Years

-1.88%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

BIOCON LIMITED. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
17.97%
Promoter Holdings
60.63%
FII
5.66%
DII
15.72%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Kiran Mazumdar Shaw 4.8458197E8 (40.36%) Shareholding of Promoter and Promoter Group
Glentec International 2.37211164E8 (19.76%) Shareholding of Promoter and Promoter Group
Lici Ulip-growth Fund 6.4079812E7 (5.34%) Public Shareholding
Sbi Healthcare Opportunities Fund 4.1179699E7 (3.43%) Public Shareholding
Kotak Equity Opportunities Fund 1.5346134E7 (1.28%) Public Shareholding
Nippon Life India Trustee Ltd-a/c Nippon India Vis 1.4988392E7 (1.25%) Public Shareholding
Arun Suresh Chandavarkar 1.32E7 (1.1%) Public Shareholding
Ravi Rasendra Mazumdar 5301321.0 (0.44%) Shareholding of Promoter and Promoter Group
Dev Mazumdar 929721.0 (0.08%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

BIOCON LIMITED. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
07 Jul 2023 1.5 Final 07 Jul 2023 Equity shares
30 Jun 2022 0.5 Final 01 Jul 2022 Equity shares
18 Jul 2019 0.5 Final 19 Jul 2019 Equity shares
19 Jul 2018 1.0 Final 20 Jul 2018 Equity shares
20 Jul 2017 1.0 Final 22 Jul 2017 Equity shares
17 Mar 2016 5.0 Interim 19 Mar 2016 Equity shares
09 Apr 2015 5.0 Interim 10 Apr 2015 Equity shares
10 Jul 2014 5.0 Final 12 Jul 2014 Equity shares
11 Jul 2013 5.0 Final 13 Jul 2013 Equity shares
11 Jul 2013 2.5 Special 13 Jul 2013 Equity shares
05 Jul 2012 5.0 Final 07 Jul 2012 Equity shares
07 Jul 2011 3.0 Final 09 Jul 2011 Equity shares
05 May 2011 1.5 Interim 06 May 2011 Equity shares
08 Jul 2010 3.5 Final 10 Jul 2010 Equity shares
13 Jul 2009 3.0 Final 10 Jul 2009 Equity shares
03 Jul 2008 3.0 Final 05 Jul 2008 Equity shares
03 Jul 2008 2.0 Special 05 Jul 2008 Equity shares
28 Jun 2007 3.0 Final 02 Jul 2007 Equity shares
29 Jun 2005 0.0 Final 10 Jul 2005 Equity shares
Ex-Date Ex-Bonus Ratio
13 Jun 2019 12 Jun 2019 1:1
17 Jun 2017 15 Jun 2017 2:1
12 Sep 2008 11 Sep 2008 1:1
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
07 Jul 2023 1.5 Final 07 Jul 2023 Equity shares
30 Jun 2022 0.5 Final 01 Jul 2022 Equity shares
18 Jul 2019 0.5 Final 19 Jul 2019 Equity shares
19 Jul 2018 1.0 Final 20 Jul 2018 Equity shares
20 Jul 2017 1.0 Final 22 Jul 2017 Equity shares
17 Mar 2016 5.0 Interim 19 Mar 2016 Equity shares
09 Apr 2015 5.0 Interim 10 Apr 2015 Equity shares
10 Jul 2014 5.0 Final 12 Jul 2014 Equity shares
11 Jul 2013 5.0 Final 13 Jul 2013 Equity shares
11 Jul 2013 2.5 Special 13 Jul 2013 Equity shares
05 Jul 2012 5.0 Final 07 Jul 2012 Equity shares
07 Jul 2011 3.0 Final 09 Jul 2011 Equity shares
05 May 2011 1.5 Interim 06 May 2011 Equity shares
08 Jul 2010 3.5 Final 10 Jul 2010 Equity shares
13 Jul 2009 3.0 Final 10 Jul 2009 Equity shares
03 Jul 2008 3.0 Final 05 Jul 2008 Equity shares
03 Jul 2008 2.0 Special 05 Jul 2008 Equity shares
28 Jun 2007 3.0 Final 02 Jul 2007 Equity shares
29 Jun 2005 0.0 Final 10 Jul 2005 Equity shares
Ex-Date Ex-Bonus Ratio
13 Jun 2019 12 Jun 2019 1:1
17 Jun 2017 15 Jun 2017 2:1
12 Sep 2008 11 Sep 2008 1:1
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

Biocon Share Result Highlights

Metric

Value

Share Price

₹325.45 (as of 07 Nov 2024)

Daily Change

+2.60 (0.80%) (as of 07 Nov 2024)

Day Range

Low: ₹322.15, High: ₹328.35 (07 Nov 2024)

52-Week Range

Low: ₹222.55, High: ₹395.80 (2024)

Market Capitalization

₹39,073.53 Cr (as of 07 Nov 2024)

PE Ratio (TTM)

922.14 (as of 07 Nov 2024)

Earnings Per Share (EPS)

₹0.35 (TTM as of 07 Nov 2024)

Dividend Yield

0.15% (as of 07 Nov 2024)

Total Traded Volume

11,44,939 shares (as of 07 Nov 2024)

Upper Circuit Limit

₹355.10 (as of 07 Nov 2024)

Lower Circuit Limit

₹290.60 (as of 07 Nov 2024)

Key Highlights

  • In 2024, Biocon share price reached a 52-week low of ₹222.55 and a high of ₹395.80.

  • Biocon’s market cap is valued at ₹39,073.53 Cr as of 07 Nov 2024.

  • A PE ratio of 922.14 reflects Biocon’s high valuation relative to earnings, as of TTM ending 07 Nov 2024.

Biocon Share Annual Reports

Metric

Value

Revenue

₹525.40 Cr (for quarter ending Sep 2024)

Operating Expense

₹578.00 Cr (for quarter ending Sep 2024)

Net Profit

₹3.20 Cr (for quarter ending Sep 2024)

Net Profit Margin

0.60% (for quarter ending Sep 2024)

Earnings Per Share (EPS)

₹0.03 (for quarter ending Sep 2024)

EBITDA

₹111.10 Cr (for quarter ending Sep 2024)

Effective Tax Rate

84.68% (for quarter ending Sep 2024)

Dividend Yield

0.15% (as of 07 Nov 2024)

52-Week Range

Low: ₹222.55, High: ₹395.80 (for 2024)

Key Highlights

  • Revenue for Biocon reached ₹525.40 Cr for the quarter ending Sep 2024.

  • Despite operating expenses of ₹578.00 Cr, Biocon maintained a net profit of ₹3.20 Cr.

  • EPS was relatively low at ₹0.03, reflecting earnings for the quarter ending Sep 2024.

  • Dividend yield stands at 0.15% as of 07 Nov 2024, offering shareholders a modest return.

Biocon Share Dividend

Dividend Details

Value

Latest Dividend Amount

₹1.5 per share (07 Jul 2023)

Dividend Type

Final Dividend (07 Jul 2023)

Previous Dividend

₹0.5 per share (30 Jun 2022)

Dividend Frequency

Annual

Dividend Yield

0.15% (as of 07 Nov 2024)

Historical Dividend Amounts

₹1 per share (20 Jul 2018), ₹5 per share (17 Mar 2016)

Key Highlights

  • The most recent Biocon share dividend was ₹1.5 per share, declared on 07 Jul 2023.

  • Biocon has maintained an annual dividend frequency, with varying amounts over the years.

  • In 2024, dividend yield stands at 0.15%, reflecting a steady return for shareholders.

  • Historical dividends include ₹1 per share in 2018 and a high of ₹5 per share in 2016.

BIOCON LIMITED. Share Price

Biocon Limited is India's largest and fully-integrated, innovation-led biopharmaceutical company. Biocon, with its key business verticals of
Generics, Biosimilars, Research Services and Novel Biologics, has leveraged its affordable innovation model and scientific capabilities to develop and manufacture both small and large molecules at global scale for the benefit of patients. At present, Company is engaged in the manufacture of biotechnology products and research services.

Biocon Limited was incorporated in year 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw. Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind. In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International. Also in the same year, the company had received US funding for proprietary technologies. After a year, in 1990, Biocon had scaled up its in-house research programme, based on a proprietary solid substrate fermentation technology, from pilot to plant level. Biocon's R&D and manufacturing facilities received ISO 9001 certification from RWTUV, Germany during the period of 1993. In the year 1994, the company had established the Syngene International Pvt. Ltd. as a Custom research Company (CRC) to address the growing need for outsourced R&D in the pharmaceutical sector. The commercial success of Biocon's proprietary fermentation plant leads to a 3-fold expansion during the year 1996 and also in the same year, the company had leveraged its technology platform to enter biopharmaceuticals and statins. Biocon had spearheads initiatives in human healthcare in the year 1997 through a dedicated manufacturing facility.

During the year 1998, Unilever inked a deal with ICI to sell its specialty chemicals division of which Quest International is a part. Unilever agreed to sell its shareholding in Biocon to the Indian promoters. Biocon becomes an independent entity in same period. In the year 2000, Biocon had commissioned its first fully automated submerged fermentation plant to produce specialty pharmaceuticals and also in the same year, the company had established Clinigene, India's first Clinical Research Organisation (CRO) to pursue clinical research and development. During the year 2001, Biocon becomes the first Indian company to be approved by US FDA for the manufacture of lovastatin, a cholesterol-lowering molecule. During the same year of 2001, the company's proprietary bioreactor, PlaFractor was granted a US 2001 and worldwide patent. Later on, in 2002, Clinigene's clinical laboratory of the company received CAP accreditation as the first in India. The Company had developed the human insulin on a Pichia expression system in the year 2003. Biocon created a buzz in the stock market in March of the year 2004 with its hugely successful IPO. Day 1 on the bourses closed with a market value of $1.11 billion, making Biocon only the second Indian company to cross the $1 billion mark on the first day of listing. During the same year 2004, the Syngene had established new research centre, launched INSUGEN, the new generation bio-insulin, manufactured in Asia's largest human insulin plant.

Biocon Limited and Vaccinex, Inc, collectively announced a broad strategic partnership to discover and co-develop at least four therapeutic antibody products. Biocon had signed a commercial agreement for supply of insulin API to Asia, Africa and the Middle East during the period of 2005. During the year 2006, the company inaugurated Biocon Park, India's largest integrated biotechnology hub, comprising an integrated cluster of research laboratories and manufacturing facilities spread across 90 acres in KIADB (Karnataka Industrial Areas Development Board) industrial estate and also established Biocon Biopharmaceuticals, India's largest multi-product Biologics facility at Biocon Park. In the same year 2006, Biocon's Syngene and Innate Pharmaceuticals AB, Umea, Sweden conclude a cooperation agreement to jointly develop, manufacture and market virulence blockers to counteract bacterial diarrhoeal disease and also launched India's first anti-cancer drug BIOMAb EGFR.

Abu Dhabi based pharmaceutical company Neopharma had signed an MOU with the company to establish a JV to manufacture and market a range of biopharmaceuticals for the GCC countries (Gulf Cooperation Council) in the year 2007. The Company launched its Nephrology Division and a comprehensive portfolio of renal therapy products. Syngene had entered into a research partnership with Bristol-Myers Squibb and completes the groundbreaking ceremony of new research facility at Biocon Park. During the identical year of 2007, Biocon signed Memorandum of Understanding with Deakin University, Australia to establish Deakin Research Institute in Bangalore. The Company divested its enzymes division for USD 115 million to Novozymes. Biocon and Neopharma signed an MOU in July of the year 2007 to establish Neobiocon, a joint venture company in Dubai's biotechnology and research park, Dubiotech.

As at January 2008, Biocon Limited and IATRICa, Inc made a strategic partnership to co-develop an exclusive new class of immunoconjugates for targeted immunotherapy of cancers and infectious diseases. In February of the year 2008, the company had acquired 78% stake in German pharmaceutical company, AxiCorp GmbH for a consideration of 30 million Euros. As at June 2008, Biocon launched a Safety Device in the form of pre-filled syringes for two of its life saving products, GCSF (granulocyte-colony stimulating factor) and EPO (Erythropoietin) in collaboration with Safety Syringes Inc. During the year, Biocon wass ranked among the top 20 global biotechnology companies and 7th largest biotech employer in the world (Med Ad News). Also during the year, Biocon announced the results of an ascending dose study on its oral insulin drug (IN-105) at the European Association for the Study of Diabetes (EASD) meeting in Rome.

In 2009, Biocon launched BASALOG - long lasting basal insulin for Type 1 & Type 2 Diabetics. During the year, the company inked partnership with ISB to launch the Biocon Cell for Innovation Management. During the year, Biocon announced Strategic Collaboration with Mylan to enter the Global Generic Biologics Market.

During the year, Biocon Limited and Amylin Pharmaceuticals entered into a Global Development and Commercialization Agreement for a Novel Peptide Hybrid. The Program will focus on the potential treatment of diabetes. Also during the year, Biocon and HCG group of hospitals joined hands in fight against cervical.

In 2010, Biocon and Bayer joined hands to create awareness for self monitoring for diabetics. During the year, Biocon acquired the stake of its Cuban partner CIMAB S.A. in their seven year old JV, Biocon Biopharmaceuticals Pvt. Ltd. In 2010, Biocon and Optimer Pharmaceuticals announced manufacturing and supply agreement for a novel API, first-in-class anti-infective (C. difficile). During the year, Biocon and the Center of Molecular Immunology (CIM), based in Havana, Cuba strengthened their existing research partnership by joining forces for an integrated antibody program in immunology. During the year, Biocon announced a strategic foreign direct investment in Malaysia with the Malaysian Biotechnology Corporation SdnBhd (BiotechCorp).

In 2011, Biocon sold its stake in its German subsidiary, AxiCorp GmbH, to the existing group of promoter shareholders. AxiCorp was the licensee for Biocon's biosimilar Insulin and Glargine in Germany and had the sole responsibility for commercializing these products. As a consequence of this divestment, these rights revert to Biocon. In 2011, Biocon announced project commencement for first high-end biopharmaceutical manufacturing and R&D facility in Bio-XCell, Malaysia. During the year, Biocon launched INSUPen, a convenient and affordable reusable insulin delivery device.In 2012, Biocon announced positive results from its Global Phase 3 study with Recombinant Human Insulin. During the year, GE Capital announced investment in Syngene, Biocon's Research Services Subsidiary. During the year, Biocon announced Positive Efficacy Data from Phase 3 clinical study with its Novel Monoclonal Antibody, Itolizumab for Psoriasis. Biocon also announced positive results from its Phase 1 Comparative PK-PD Study with Biosimilar Insulin Glargine. During the year, Biocon entered into an agreement with Bristol-Myers Squibb for its IN-105, an Oral Insulin drug.

In 2013, Biocon received Marketing Authorization from the Drugs Controller General of India (DCGI) for its Novel Biologic Itolizumab, anti CD6 molecule, for the treatment of chronic plaque Psoriasis. During the year, Biocon expanded its partnership with Mylan through Strategic Collaboration for Insulin Products. In 2013, Biocon launched ALZUMAb- a 'First in Class' Novel Biologic Treatment for Psoriasis Patients in India. During the year, Biocon partnered with CytoSorbents to Market CytoSorb - A 'First-in-Class' Therapy for Sepsis Management. During the year, Biocon and Mylan received Indian Regulatory Approval for Trastuzumab for Treating Breast Cancer. In 2013, Biocon and Quark Pharmaceuticals announced collaboration to Develop Novel siRNA based Therapeutics.

In 2014, Biocon introduced CANMAb - Trastuzumab for treating Breast Cancer in India. During the year, Silver Leaf Oak (Mauritius) Limited, an investment vehicle advised by India Value Fund Advisors agreed to acquire a minority 10% stake in Syngene International Limited, Biocon's Research Services subsidiary. Silver Leaf will acquire the stake from Biocon Research Limited, a wholly owned subsidiary of Biocon Limited at a valuation of Rs 3800 crore. During the year, Biocon expanded its Strategic Partnership with CytoSorbents to treat SIRS and Cardiac Surgery Patients.

In 2015, Biocon commissioned Asia's largest integrated insulin manufacturing facility at the Biotech Park in Johor, Malaysia. During the year, Biocon received approval in Mexico for Insulin Glargine through its partner PiSA Farmaceutica. During the year, Biocon's Research Services subsidiary Syngene International was listed on the bourses after an initial public offer (IPO). In 2015, Biocon inaugurated a World Class devices facility in Bangalore and introduced Basalog One in India.

In 2016, Mylan and Biocon announced USFDA submission for proposed Biosimilar Trastuzumab. Mylan and Biocon also announced that regulatory submission for Insulin Glargine and proposed Biosimilar Pegfilgrastim were accepted for review by European Medicines Agency. During the year, Biocon launched its Insulin Glargine in Japan. During the year, Biocon and Quark announced initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India. During the year, Biocon received its first generic formulation approval in European Union. Also during the year, Biocon signed Co-Development & Commercialization Agreement with Lab PiSA for rh-Insulin in USA.

In 2017, USFDA accepted Biologics License Application (BLA) for Mylan and Biocon's proposed Biosimilar Pegfilgrastim for review. During the year, Biocon started commercial operations at its Malaysia facility with MYR 300 million contract from MoH, Malaysia to supply rh-insulin. During the year, USFDA accepted Biologics License Application (BLA) for Mylan and Biocon's proposed Biosimilar Trastuzumab.

On 18 January 2018, Biocon and Sandoz, a Novartis division and a global leader in biosimilars, announced a global partnership to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide. Under the terms of the agreement, both companies will share responsibility for end-to-end development, manufacturing and global regulatory approvals for a number of products and will have a cost and profit share arrangement globally. Worldwide commercialization responsibilities will be divided and each company's strengths will be leveraged within specific geographies. Sandoz will lead commercialization in North America and the EU while Biocon will lead commercialization in Rest of the World.

On 29 January 2018, Mylan N.V., one of the world's leading pharmaceutical companies, and Biocon announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Semglee, insulin glargine, a long-acting insulin analog used in the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. Biocon and Mylan are exclusive partners on a broad portfolio of biosimilars and insulin analogs.Mylan and Biocon on 28 March 2018 announced that their co-developed biosimilar insulin glargine Semglee has received marketing authorization approval from the European Commission (EC) following the positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) of European Medicines Agency. Semglee 100 units/mL 3 mL prefilled disposable pen for people with diabetes, is the first biosimilar from Biocon and Mylan's joint portfolio to be approved in Europe. The EC approval of Semglee applies to all 28 European Union (EU) member states and the European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein. Additionally, the Therapeutic Goods Administration (TGA), Australia has also approved biosimilar insulin glargine Semglee 100 IU/mL 3 mL prefilled pen for the people with diabetes in Australia.

On 11 April 2018, Biocon announced that the company and Mylan have agreed to accelerate introduction of adalimumab biosimilar in Europe through Mylan's in-licensing arrangement with Fujifilm Kyowa Kirin Biologics (FKB). FKB's product is at an advanced stage of review and could potentially obtain approval in Europe in the second half of 2018. Through this arrangement, Mylan could commercialize FKB's Adalimumab in EU around market formation. Biocon retains its economic interest in this arrangement vis-a-vis Mylan in line with its existing global collaboration with Mylan for monoclonal antibodies.

During FY'19, Company's first Generic Formulations plant, commissioned in 2017, received U.S. FDA approval. It commercialized Ogivrir* (Trastuzumab) in Europe. It signed agreement with GSK to advance drug discovery in multiple therapy areas. It signed agreement with Biotechnology Industry Research Assistance Council (BIRAC) to set up a Centre for Advanced Protein Studies.

In FY'21, Company launched Tacrolimus capsules, Biocon's first immunosuppressant formulation in the U.S., for the benefit of organ transplant patients. It also entered new partnerships to expand commercial footprint to Singapore, Thailand and Brazil. It received U.S. FDA approval for Everolimus (gAfinitor), an immunosuppressant formulation to prevent rejection of organ transplants, and treat renal cell cancer and other tumors. It entered into a partnership with Libbs Farmaceutica, marking the entry of Biocon's Generic Formulations into Latin America, starting with Brazil. It partnered with DKSH to expand access to Biocon's Generic Formulations portfolio in key South East Asian markets of Singapore and Thailand. It continued to build Generic Formulations portfolio through new regulatory filings in the U.S., EU and Most of World markets. It received a GMP compliance certificate from MHRA, UK, for Generic Formulations manufacturing facility at Biocon Park in Bengaluru. It extended till 2030, a long-standing partnership with Bristol Myers Squibb (BMS) for drug discovery research. It entered a 5-year pact with 3DC, the drug discovery and development unit of Deerfield Management Co, to advance therapeutic discovery projects. It helped partner Albireo Pharma advance their compound to regulatory filings in U.S. and Europe, putting it on track to be the first approved drug for treating specific genetic liver diseases, primarily in children. It continued to support clients on drug research projects for leukemia, Parkinson's disease, inflammatory disorders, fibrotic disorders and orphan diseases. It expanded research facility in Hyderabad by adding capacity for an additional 90 scientists. It commissioned a new microbial manufacturing facility to reduce dependency on external service providers. It commercialized third biosimilar, Insulin Glargine, in the U.S. and obtained regulatory approvals for key biosimilars Bevacizumab and Insulin Aspart in the European Union. Its biosimilars benefited 3.1 million patients during the year. In association with partner, Viatris, the Company commercialized bGlargine (Semglee) in the U.S. and Fulphila in Australia and Canada. Its product pipeline got a boost with approvals from European Commission for biosimilar Bevacizumab and biosimilar Insulin Aspart, co-developed with Viatris. It commenced a multiple ascending doses (MAD) study for Type 1 DM in Germany in FY20, in partnership with the U.S.-based Juvenile Diabetes Research Foundation (JDRF) for Insulin Tregopil. Itolizumab, was granted Restricted Emergency Use approval in July 2020 to treat Cytokine Release Syndrome (CRS) in moderate to severe Acute Respiratory Distress Syndrome (ARDS) patients in India. The drug was subsequently made available in the domestic market, having benefited over 27,000 patients as of May 2021. BCA101, the lead program for Boston-based Bicara Therapeutics, a first-inclass EGFR / TGFß-trap bifunctional antibody, entered a Phase 1/2 study at leading U.S. and Canadian cancer centers in July 2020. It ceded control over the Board and operations of Bicara Therapeutics, which housed our immuno-oncology program focused on developing novel bifunctional fusion antibodies. It received approval for Bevacizumab from the National Pharmaceutical Regulatory Agency (NPRA) in Malaysia. In July 2021, the European Medicines Agency's Committee for Orphan Medicinal Products granted an orphan medical product designation to Itolizumab for the treatment of both acute and chronic GVHD. This was a milestone for the Company as it intend to develop this drug for patients in Europe upon regulatory approval.

In FY'22, the Company launched five products in the U.S. It strengthened its U.S. formulations portfolio with the launch of Labetalol Hydrochloride tablets and Esomeprazole Magnesium Delayed-Release capsules. It received approval from the U.S. FDA for ANDA for Mycophenolic Acid, which is indicated for the prophylaxis of organ rejection in adult patients receiving kidney transplants. It commenced first Most of the World (MoW) market supply of Tacrolimus capsules to Mexico, and received its first approval for Tacrolimus in Singapore, and for Rosuvastatin and Tacrolimus in the UAE. It also obtained Marketing Authorization for Everolimus tablets in the Netherlands and Spain. It received a Certificate of Good Distribution Practice (GDP) Compliance of a Wholesale Distributor from the Maltese authorities for the import and marketing of drug products in the European Union. More recently, it received a Compliant rating from Health Canada for API manufacturing facility in Bengaluru. It signed a strategic alliance with Serum Institute Life Sciences, marking an asset-light' and accelerated entry into vaccines. It advanced two unpartnered antibody programs, bUstekinumab and bDenosumab, to the clinical phase. It executed a Day 1' U.S. launch of Everolimus 10 mg tablet, a generic formulation for treating certain cancers and tumors. In FY22, it completed 34 product filings globally for APIs, including five in the U.S., and 28 filings for formulations, out of which 11 were in the U.S. It signed a partnership deal with Tabuk Pharmaceutical Manufacturing Company, a fully-owned subsidiary of Astra Industrial Group, to commercialize select specialty generic medicines in the Middle East region, expanding the global presence of the Generic Formulations business. It received several product approvals in Most of the World (MoW) markets in FY'22.

During the year 2022, Company went through various regulatory audits at some of its key sites, with successful outcomes. At the Oral Solid Dosage (OSD) facility in Bengaluru, the U.S. FDA conducted a Remote Interactive Evaluation (RIE) in September 2021, which was a pre-approval review for ANDAs filed earlier. The facility also secured a certificate of Good Manufacturing Practice (GMP) from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K. based on a remote inspection. The certificate included manufacturing and packaging of tablets and capsules in the nonpotent and potent blocks of the facility. Furthermore, the Maltese authorities conducted a Wholesale Dealer License (WDL) and Manufacturing/ Importation Authorization (MIA) inspection, and thereafter, granted Company a Certificate of Good Distribution Practice (GDP) of a Wholesale Distributor, that enabled to import and market products in the European Union. Towards the end of the fiscal, Health Canada also conducted a remote inspection of API manufacturing unit in Bengaluru and rated it as Compliant' It commenced clinical trials for two of its unpartnered assets, bUstekinumab for inflammatory conditions and bDenosumab to treat osteoporosis and cancer. It received favorable rulings from the U.S. Federal Circuit related to patents covering the originator's device and formulation for administering bGlargine.

During 2022-23, the Company commissioned its greenfield, fermentation-based immunosuppressant API manufacturing facility in Visakhapatnam, Andhra Pradesh and peptides API manufacturing facility in Bengaluru. It began work on expanding synthetic and non-immunosuppressant fermentation capacities in addition to a new injectable facility. Two important APIs, Sitagliptin and Vildagliptin were launched in the European Union. bBevacizumab was launched in 12 countries; a new insulin analog from ' bAspart' portfolio was launched in Canada and Malaysia. In FY23, the Company launched five generic formulation products. In the UK, it launched Posaconazole and in the European Union, Rosuvastatin.

In FY 2024, Company launched two products in the U.S., Liothyronine Sodium tablets and Famotidine oral suspension. In line with Most of the World (MoW) expansion strategy, it launched Mycophenolic Sodium tablets in Israel, the first drug product in this country, and Everolimus
tablets in Saudi Arabia. It acquired an oral solid dosage manufacturing facility in Cranbury, New Jersey, US. It commenced construction of new injectables facility at Biocon Park in Bengaluru. It expanded the patient reach through 25 new launches. It acquired a multi-modal biologics manufacturing facility from Stelis Biopharma Ltd. A state of the art, digitally enabled Quality Control laboratory to support the growing biologics operations got commissioned, followed by the commissioning of centralized compound management facility in Hyderabad.

Parent organization Indian Private
NSE symbol BIOCON
Founded 1978
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Biocon Ltd?

Answer Field

The share price of Biocon Ltd for NSE is ₹ 321.8 and for BSE is ₹ 321.7.

What is the Market Cap of Biocon Ltd?

Answer Field

The market cap of Biocon Ltd for NSE is ₹ 3,86,35.31 Cr. and for BSE is ₹ 3,86,23.30 Cr. as of now.

What is the 52 Week High and Low of Biocon Ltd?

Answer Field

The 52 Week High and Low of Biocon Ltd for NSE is ₹ 404.70 and ₹ 269.55 and for BSE is ₹ 404.60 and ₹ 270.00.

How to Buy Biocon Ltd share?

Answer Field

You can trade in Biocon Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Biocon Ltd?

Answer Field

The 1 year returns on the stock has been 7.78%.

What is the Current Share Price of Biocon Ltd?

Answer Field

Biocon Ltd share price is for NSE ₹ 321.8 & for BSE ₹ 321.7 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Biocon Ltd Share?

Answer Field

The market cap of Biocon Ltd for NSE ₹ 3,86,35.31 & for BSE ₹ 3,86,23.30 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Biocon Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Biocon Ltd share is 64.21.

What is the PB ratio of Biocon Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Biocon Ltd share is 90.69.

How to Buy Biocon Ltd Share?

Answer Field

You can trade in Biocon Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Biocon Ltd Share on Bajaj Broking App?

Answer Field

To buy Biocon Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Biocon Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

Who is the CEO of Biocon Ltd?

Answer Field

Siddharth Mittal has served as CEO of Biocon Ltd since 1 December 2019. He leads Biocon’s strategic direction, focusing on the company’s growth in biopharmaceuticals and driving its innovations in the global market.

When was Biocon Ltd established?

Answer Field

Biocon Ltd was established in 1978. It began as a joint venture with Biocon Biochemicals Ltd, Ireland, and has since evolved into a leading biotechnology company, making significant contributions in biopharmaceuticals.

What factors influence the Biocon Share Price?

Answer Field

The Biocon Share Price is influenced by various factors, including quarterly earnings, regulatory changes, market trends, and developments within the biotechnology sector. Economic conditions and investor sentiment also play a role.

Is Biocon Ltd debt-free?

Answer Field

No, Biocon Ltd is currently not debt-free. The company strategically uses debt to finance its operations, support expansion plans, and invest in research and development within the biopharmaceutical industry.

What is the CAGR of Biocon Share?

Answer Field

The Compound Annual Growth Rate (CAGR) of Biocon Share over different time frames is 16% over 10 years, 4% over 5 years, -3% over 3 years, and 42% over 1 year.

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|